Dr. Sally Fischer

Sally has been a member of Genentech Bioanalytical Sciences (BAS) department for the past 18 years. She leads leading a group responsible for development and implementation of assay strategies to evaluate the pharmacokinetics (PK), anti-drug antibodies (ADA) as well as biomarkers to support Genentech studies and enable IND, BLA, NDA and related filings. Her group’s focus is to provide data that will support development of novel therapeutics in both immunology and neuroscience therapeutic areas in the Genentech development pipeline. Sally also leads a Genentech wide forum focussing on evaluation and implementation of new immunoassay technologies as well as innovative patient centric healthcare solutions to enable development of complex molecules designed to improve patients’ lives.

“Microsampling or home testing is the future of health care as we move toward patient centric treatment and individualized solutions. Advances in this area have a potential to increase medical access to patients, increase clinical trial participation, and reduce drug development timelines and costs.”